SCHEMBL279726

SCHEMBL279726

Cc1ccc(S(=O)(=O)CNc2cccnc2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.46
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 5/20 0.41
TP53 P04637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 3/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 2/20 0.38
S1PR4 O95977 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38
S1PR1 P21453 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280357 0.80 ALDH1A1 (0.45) NAMPTRAB9AALDH1A1TP53TDP1
SCHEMBL10503680 0.70 CA12 (0.62) NAMPTRAB9AALDH1A1TP53KDM4E
SCHEMBL10503692 0.70 SMN1; SMN2 (0.47) NAMPTRAB9AALDH1A1TP53KDM4E
SCHEMBL2441007 0.68 RAB9A (0.53) NAMPTRAB9AGAALMNAPOLB
SCHEMBL1355489 0.65
SCHEMBL14625554 0.65 L3MBTL1 (0.64) NAMPTRAB9AKMT2AMEN1LMNA
Hydrochloric Acid SCHEMBL10704335 0.64 RAB9A (0.56) RAB9AALDH1A1KDM4EGAALMNA
Hydrochloric Acid SCHEMBL28089121 0.64 RAB9A (0.56) RAB9AALDH1A1KDM4EGAALMNA
SCHEMBL6739276 0.63 LMNA (0.56) ALDH1A1TP53KDM4EGAATSHR
SCHEMBL3643530 0.62 RAB9A (0.54) RAB9AALDH1A1GAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL NAMPT 1398/4885RAB9A 2458/4885ALDH1A1 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.